FDA has granted Annamycin fast-track eligibility to treat AML

recently, Moleculin Biotech(http:// announcedthat the U.SFDA(http://has granted Annamycin (Anamamycin) fast-track eligibility to treat recurrent or refractory acute myeloid leukemia (AML)About Annamycin
Annamycin is a new generation of cyclocyclo-
drug(http://(http:// that has little cardiac toxicity and avoids multidrug resistance, exhibits greater efficacy in AML cell lines, and efficacy in patients who fail to treat standard care therapyCurrently, Annamycin is being developed for the treatment of patients with recurrent or refractory AMLDoxorubicin, one of the main cyclocycling drugs used in induction therapy for patients with acute leukemia, is reported to have an annual revenue of more than $700 millionAlthough approved cyclomydrugs, such as amycin, are important and successful, they are both heart toxic, which can cause heart damage and limit the dose of administrationin addition, treated tumor cells are often resistant to first-line cyclocycling drugs, often through so-called "multidrug resistance" that enables them to remove current cyclocosis and limit the effectiveness of treatment As a result, for the vast majority of patients, there is still no effective treatment, and the majority of patients will soon die of leukemia 　　Annamycin has the opportunity to become a game-changer in this regard The drug is a unique, new generation of liposome formula ring-like drugs (also known in the literature as "L-Annamycin" ) designed to eliminate cardiac toxicity and avoid the multidrug resistance mechanism that often defeats currently approved steroids In animal models that tested cardiac toxicity, Annamycin was shown to be non-cardiac toxic, and in the (http:// of a human clinical with a focus on leukemia, the drug showed a much less dose of restricted toxicity than amycin, one of the main first-line cyclocycling drugs used to induce treatment 　　Annamycin has previously been tested in six clinical trials and 114 patients, including two clinical trials focusing on leukemia, to treat patients with recurrent or difficult treatment of first-line induction therapy, which have little or no reported cardiac toxicity